NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Sorry Doc, I got confused. You were writing about the effectiveness of DCVax-L in methylated mesenchymal GBM which is a far less pernicious cancer than the unmethylated form and I was referring to generally to mesenchymal cancer.

DCVax-L seems to have some value for GBM patients with the unmethylated form of mesenchymal GBM as I believe the 2018 JTM stated that about 14% of the blended patients with the unmethylated GBM were destined to become post 36 months survivors. That is a promising result especially since it included Control patients with the unmethylated form.

However, I agree that the real homerun will emerge from the methylated mesenchymal Treatment group.